TY - JOUR
T1 - Intraislet glucagon signaling is critical for maintaining glucose homeostasis
AU - Zhu, Lu
AU - Dattaroy, Diptadip
AU - Pham, Jonathan
AU - Wang, Lingdi
AU - Barella, L. F.
AU - Cui, Yinghong
AU - Wilkins, Kenneth J.
AU - Roth, Bryan L.
AU - Hochgeschwender, Ute
AU - Matschinsky, Franz M.
AU - Kaestner, Klaus H.
AU - Doliba, Nicolai M.
AU - Wess, Jürgen
N1 - Publisher Copyright:
© 2019 American Society for Clinical Investigation.
PY - 2019
Y1 - 2019
N2 - Glucagon, a hormone released from pancreatic a cells, plays a key role in maintaining proper glucose homeostasis and has been implicated in the pathophysiology of diabetes. In vitro studies suggest that intraislet glucagon can modulate the function of pancreatic ß cells. However, because of the lack of suitable experimental tools, the in vivo physiological role of this intraislet cross-talk has remained elusive. To address this issue, we generated a mouse model that selectively expressed an inhibitory designer GPCR (Gi DREADD) in a cells only. Drug-induced activation of this inhibitory designer receptor almost completely shut o? glucagon secretion in vivo, resulting in markedly impaired insulin secretion, hyperglycemia, and glucose intolerance. Additional studies with mouse and human islets indicated that intraislet glucagon stimulates insulin release primarily by activating β cell GLP-1 receptors. These fndings strongly suggest that intraislet glucagon signaling is essential for maintaining proper glucose homeostasis in vivo. Our work may pave the way toward the development of novel classes of antidiabetic drugs that act by modulating intraislet cross-talk between a and ß cells.
AB - Glucagon, a hormone released from pancreatic a cells, plays a key role in maintaining proper glucose homeostasis and has been implicated in the pathophysiology of diabetes. In vitro studies suggest that intraislet glucagon can modulate the function of pancreatic ß cells. However, because of the lack of suitable experimental tools, the in vivo physiological role of this intraislet cross-talk has remained elusive. To address this issue, we generated a mouse model that selectively expressed an inhibitory designer GPCR (Gi DREADD) in a cells only. Drug-induced activation of this inhibitory designer receptor almost completely shut o? glucagon secretion in vivo, resulting in markedly impaired insulin secretion, hyperglycemia, and glucose intolerance. Additional studies with mouse and human islets indicated that intraislet glucagon stimulates insulin release primarily by activating β cell GLP-1 receptors. These fndings strongly suggest that intraislet glucagon signaling is essential for maintaining proper glucose homeostasis in vivo. Our work may pave the way toward the development of novel classes of antidiabetic drugs that act by modulating intraislet cross-talk between a and ß cells.
UR - http://www.scopus.com/inward/record.url?scp=85070658881&partnerID=8YFLogxK
U2 - 10.1172/jci.insight.127994
DO - 10.1172/jci.insight.127994
M3 - Article
C2 - 31012868
AN - SCOPUS:85070658881
SN - 2379-3708
VL - 4
JO - JCI insight
JF - JCI insight
IS - 10
M1 - e127994
ER -